• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Orig3n, Sharp Edge Labs ink drug discovery alliance

Orig3n, Sharp Edge Labs ink drug discovery alliance

March 28, 2016
CenterWatch Staff

ORIG3N, a regenerative medicine provider, and Sharp Edge Labs, a drug discovery and development company focused on genetic disorders, have entered into a drug discovery alliance. As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders.

Previously, patients only became involved in the drug discovery process at its later stages, when a compound was being tested in clinical trials. The new approach that ORIG3N and Sharp Edge Labs are undertaking will bring patient cells into the drug discovery process much earlier with the intent of creating a truly patient-driven drug discovery pipeline.

"We are now involving patients earlier in the drug discovery process this is a special moment in medicine," said Scott Sneddon, CEO of Sharp Edge Labs. "By combining our technologies, we are tailoring treatments for specific patient populations from the very beginning, with the aim of delivering disease modifying agents for diseases of high unmet need."

Sharp Edge Labs focuses on inherited diseases involving defects in protein trafficking, one of the most common cellular defects in genetic disorders. The company has a cellular imaging platform that it uses to screen for drugs that can restore proper trafficking, and has internal programs in Cystic Fibrosis, an inherited form of Parkinson's disease and Frontotemporal Dementia.

ORIG3N is transforming the future of medicine by building LifeCapsulethe world's largest biorepository of induced pluripotent stem cells (iPSC) from crowd sourced blood samples. ORIG3N is using Nobel Prize-winning technology to reprogram each blood sample into iPSCs, which are then used to grow different cell types including neurons, heart cells and liver cells. These cells offer a powerful tool for accurate disease modeling and drug discovery research.

"A patient's own cells are the best model for understanding how a disease manifests and how it responds to a drug," said Robin Y. Smith, CEO of ORIG3N. "Using iPSC technology accelerates the pace of drug development and is helping us move closer to being able to provide the right drug to the right patient and avoid the trial and error approach that often happens today."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing